搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
17 小时
BMO维持Merus 95美元目标价,基于积极的试验数据
周一,BMO Capital Markets维持了对临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)的乐观立场,重申了"优于大市"评级和95.00美元的目标价。这一背书紧随Merus宣布开始在一项关键的3期试验(名为LiGeR-HN1)中给第一位患者用药。该研究正在评估petosemtamab(也称为peto)与pembrolizumab联合用于治疗此前未经治疗的头颈部癌症患者的疗 ...
2minutemedicine.com
21 小时
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
15 小时
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
Medpage Today on MSN
14 天
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
1 天
Merus启动头颈癌治疗的3期临床试验
荷兰乌特勒支 - 临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)宣布启动一项3期临床试验,研究新型癌症治疗药物petosemtamab与pembrolizumab联合用于复发或转移性头颈部鳞状细胞癌(r/m HNSCC)患者的治疗。LiGeR-HN1试验已完成首例患者给药,该试验将比较这种联合疗法与单独使用pembrolizumab作为一线治疗的疗效和安全性。 Petosemta ...
Medscape
12 天
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
阿思達克財經網
6 天
FDA咨询委员会将聚焦施贵宝(BMY.US)和默沙东(MRK.US)的检查点抑制剂
无论肿瘤的PD-L1表达如何,Opdivo和Keytruda都在这两种适应症中获得了批准。然而,FDA表示,越来越多的证据表明,PD-L1的表达可以作为药物在这一人群中疗效的预测性生物标志物。
Medscape
14 天
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
oncnursingnews
15 天
Pembrolizumab Plus Chemoradiotherapy May Be New Standard in Locally Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
8 小时
Buy Rating Affirmed for Merus on Strong Clinical Trial Progress and Competitive Positioning
Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), retaining the price target of $100.00.
Targeted Oncology
15 天
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈